Citigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50

Benzinga · 1d ago
Citigroup analyst Joanne Wuensch downgrades Boston Scientific (NYSE:BSX) from Buy to Neutral and lowers the price target from $57 to $50.